SCHEMBL8096149

SCHEMBL8096149

CCCCOc1nc(OCCCC)n(Cc2ccc(Cc3ccccc3-c3nnn[nH]3)cc2)n1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 15/20 0.36
AGTR1 P30556 1/20 0.34
AGTR2 P50052 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8105347 0.95 PDE5A (0.35) TLR7
SCHEMBL8109185 0.89 AGTR1 (0.42) AGTR1AGTR2
SCHEMBL8109435 0.83 AGTR1 (0.39) AGTR1AGTR2
SCHEMBL8109235 0.83 TLR7 (0.34) TLR7AGTR1AGTR2
SCHEMBL8103400 0.81 AGTR1 (0.34) TLR7AGTR1AGTR2
SCHEMBL8111064 0.81
SCHEMBL8103383 0.79 PDE5A (0.33) TLR7
SCHEMBL9527516 0.79 AGTR1 (0.53) AGTR1AGTR2
SCHEMBL8111258 0.78 AGTR1 (0.46) AGTR1AGTR2
SCHEMBL8105370 0.78 AGTR1 (0.57) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3098772-B2 2000-10-16 JP claimed
EP-0527851-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-02-24 EP claimed
WO-1991017148-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-11-14 WO claimed
EP-0527851-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-02-24 EP disclosed
US-5098920-A Hypotensive agents and treatment of congestive heart failure G. D. SEARLE & CO. (US) 1992-03-24 US disclosed
WO-1991017148-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-11-14 WO disclosed